Beyond Generics: The Rise of Biosimilars in Modern Medicine

Beyond Generics: The Rise of Biosimilars in Modern Medicine
Biosimilars Market
Biosimilars Market Analysis and Forecast to 2033: By Product (Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, and Others), Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, and Others), and Region.

Market Definition:

Biosimilars are biological products that are approved by the FDA to be highly similar to an already-approved biological product, known as a reference product. Biosimilars are also called subsequent entry biologics (SEBs). Biosimilars can be used to treat the same conditions as the reference product.

The FDA has a pathway for approving biosimilars that meets the requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The pathway includes showing that a biosimilar has the same high level of safety and effectiveness as the reference product. The FDA has approved several biosimilars, and more are in development.

To Know More:

Market Outlook:

The biosimilars market is expected to grow significantly in the next few years. The key drivers of this growth include the expiry of patents for biologic drugs, the increasing number of biosimilar products in development, and the growing awareness of biosimilars among patients and healthcare providers. 

The number of biosimilar products in development has increased significantly in recent years. In Europe, there are currently more than 100 biosimilar products in clinical development, and this number is expected to grow in the coming years. In the United States, the FDA has approved several biosimilar products, and more are in development.

The increasing awareness of biosimilars among patients and healthcare providers is also driving growth in the market. Biosimilars are often seen as a more affordable alternative to biologic drugs, and they are also associated with a lower risk of adverse events.

The key trends in biosimilars technology are the increasing number of products in development, the growing awareness of biosimilars, and the increasing use of biosimilars in clinical practice.

Key Drivers

The key drivers of the biosimilars market are the expiry of patents for biologic drugs, the increasing prevalence of chronic diseases, and the growing demand for biologic drugs.

The expiry of patents for biologic drugs is the primary driver of the biosimilars market. Biologic drugs are large, complex molecules that are difficult to replicate. As a result, when patents for these drugs expire, there are few companies that are able to produce biosimilars. The increasing prevalence of chronic diseases is also a driver of the biosimilars market. Chronic diseases, such as cancer and diabetes, require long-term treatment with biologic drugs. The growing demand for biologic drugs is also a driver of the biosimilars market. Biologic drugs are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.

Restraints & Challenges

The biosimilars market is still in its early stages of development, and there are a number of challenges that need to be addressed before it can reach its full potential. One of the key challenges is the lack of regulatory clarity around the world. In Europe, for example, biosimilars are regulated as generic medicines, while in the United States they are regulated as biological medicines. This difference in regulatory approach has created a complex and uncertain environment for biosimilar developers, which has made it difficult to bring products to market.

Another challenge facing the biosimilars market is the high cost of development. Biosimilar medicines are much more complex to develop than traditional small molecule drugs, and this complexity is reflected in the cost. It is estimated that it costs around $250 million to develop a biosimilar medicine, which is around 10 times more than the cost of developing a small molecule generic drug.

Request Sample:

Research Objectives:

•            Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

•            Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

•            Identify factors influencing market growth and challenges, opportunities, drivers and restraints

•            Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

•            Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

•            Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

•            To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

•            Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request Customization:

Key Market Segments

The biosimilars market bifurcated on the basis of product, application and region. On the basis of product it is segmented into insulin, granulocyte colony-stimulating factor, erythropoietin, and others. By application, it is spread across oncology, blood disorders, growth hormonal deficiency, and others. Region-wise, it is studied across North America, Europe, Asia-Pacific, and rest of the World.

Key Market Players:

  • Amgen (USA)
  • Mylan (USA)
  • Novartis (Switzerland)
  • Sandoz (A subsidiary of Novartis) (Switzerland)
  • Pfizer (USA)
  • Biocon (India)
  • Celltrion (South Korea)
  • Samsung Bioepis (South Korea)
  • Teva Pharmaceuticals (Israel)
  • Hospira (A subsidiary of Pfizer) (USA)

Request Discounted Pricing:

Research Scope:

•            Scope – Highlights, Trends, Insights. Attractiveness, Forecast

•            Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

•            Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

•            Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

•            Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

•            Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis

Buy your copy here:

About Us:

With Global Insight Services, you receive:

• 10-year forecast to help you make strategic decisions

• In-depth segmentation which can be customized as per your requirements

• Free consultation with lead analyst of the report

• Infographic excel data pack, easy to analyze big data

• Robust and transparent research methodology

• Unmatched data quality and after sales service


Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958


Phone: +1-833-761-1700


About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Media Contact
Company Name: Global Insight Services
Contact Person: Kabita Sahu
Email: Send Email
Country: India